Verdiva Bio, a pioneering company dedicated to revolutionizing treatments for obesity and cardiometabolic disorders, has successfully raised an impressive $410 million in funding. This significant investment will propel the company's mission to develop next-generation therapies that offer patient-friendly options, ultimately enhancing health outcomes for individuals grappling with these challenging conditions. Central to Verdiva Bio's innovative approach is its lead candidate, VRB-101, an oral GLP-1 peptide currently in clinical development. Following a promising phase 1 study in Australia, VRB-101 has exhibited best-in-class efficacy potential and confirmed the feasibility of a once-weekly dosing regimen, paving the way for a more manageable treatment experience for patients. Additionally, the company is actively advancing a diverse pipeline of amylin molecules, which encompass both oral and subcutaneous agonists, alongside other undisclosed programs specifically designed to improve efficacy, tolerability, and promote healthier weight loss. By leveraging the latest discoveries in gut-brain biology and drawing upon their experienced team’s rich history in successful drug development, Verdiva Bio is poised to make a substantial impact on the lives of millions affected by obesity and its related complications worldwide. The funding will serve as a critical catalyst, enabling Verdiva to accelerate its research and development efforts, bringing innovative treatments to market faster than ever before. For more information about Verdiva Bio and its transformative therapies, please visit www.verdivabio.com.
Elevating Healthcare Innovation: Verdiva Bio Secures $410 Million in Series A Funding
Recently funded · $410.0M Series aBiotechnology Research
Get the full Verdiva Bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)